This mechanism directly links immune dysregulation to thrombosis, with the procoagulant effect being attenuated by selective heparanase inhibition (RDS3337), suggesting a novel therapeutic target for APS-related pregnancy morbidity [55]. The gene discussed is HPSE; the disease is autoimmune polyendocrinopathy.